Head-to-head evidence
GH21 vs HBI-2376
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: SHP2 · full Non-Small Cell Lung Cancer pipeline
GH21
Developed by Suzhou Genhouse Bio Co., Ltd.
NCT05183243 · Phase 1 · status unknown
This is an early-stage, single-group dose-finding study with no randomization, no blinding, and no comparison group, designed only to establish a safe dose. Studies of this type do not provide controlled evidence of benefit, and no results are available yet.
HBI-2376
Developed by HUYABIO International, LLC.
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2026 · NCT05163028 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: GH21's landscape · HBI-2376's landscape